Product information and disease descriptionPlace of product in therapyApproaches to treatment
Care management intervention strategies
5 evidence topics · 12 sources
Immunoglobulin dose optimization and cessation trials
“Periodic IVIG optimization trials using objective outcomes are encouraged in all CIDP patients receiving chronic IVIG treatment as a means to identify the lowest effective IVIG dose and frequency.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In both groups, drug‐free remission was achieved in about one‐third of patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The successful cessation trials resulted in a cost saving of £855 000/year, with a potential further saving of £1.7 million/year if all the eligible individuals had consented.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All patients who deteriorated were rescued to previous baseline on retreatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Individuals with CIDP should be counselled about the natural history of the disease and future scheduled, targeted cessation trials. A dedicated clinical infrastructure is vital to safely perform cessation trials.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Subcutaneous immunoglobulin dose reduction
“After dose reduction from 0.4 to 0.2 g/kg, 51% (27/53) of patients relapsed, of whom 92% (24 of 26) improved after reinitiation of the 0.4 g/kg dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two-thirds of patients (19/28) who completed the PATH study without relapse remained relapse-free on the 0.2 g/kg dose after dose reduction in the extension study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Long-term dosing should be individualized to find the most appropriate dose in a given patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Home and subcutaneous administration
“Eight consecutive patients, four with MMN and four with CIDP, already on long-term, hospital-based IVIG were switched to home-based SCIG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In seven of the eight patients, SCIG gave improved tolerability and patient satisfaction with similar efficacy compared with IVIG.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most important factors in treatment decision-making were a lower chance of CIDP symptom worsening in 6 months, less frequent treatment administration, and home infusion (all p < 0.001 vs reference categories).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, like conventional SCIG, fSCIG 10% offers the potential convenience of home administration, 13 leading to possible cost savings and eliminating burden of travel to an infusion center or other facility over multiple days.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Home infusions are generally safe, effective, convenient, and less costly than infusions in other sites of care (eg, physician office, outpatient hospital), making this a frequently used site of care for infusions, either by choice or through health plan benefit design.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Outcome monitoring with disability, strength, and patient-reported scales
“Assessing strength impairment, disability, and quality of life is ideally suited for everyday practice when caring for patients with CIDP.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Such data are critically important when justifying the need for ongoing or periodic immunotherapy, documenting relapse or deterioration, or providing reassurance of disease improvement, stability, or remission.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Frequent assessment of grip strength can be a useful tool to identify intravenous immunoglobulin (IVIG) treatment‐related fluctuations (TRFs) and optimize IVIG treatment in real‐time, but the long‐term implications of TRFs are unknown.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint in stage A, evaluated in the stage A safety population, was confirmed ECI (≥1 points aINCAT decrease, ≥4 points [centile metric] Inflammatory Rasch-built Overall Disability Scale increase, or ≥8 kPa grip strength increase after four injections and two consecutive visits).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Remote monitoring of grip strength and patient-reported outcomes
“Patients were monitored weekly or monthly, based on stability and patient preference, using grip strength, modified timed‐up‐and go (mTUG), and patient‐reported outcome measures (PROMs).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adherence was 93% (95% CI: 91.9%–94.1%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Grip strength and mTUG ICCs were both 0.96 (95% CI: 0.93–0.98 and 0.92–0.99, respectively).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote